It’s hard to believe, but Dicerca’s drug trial is nearly complete.
The trial, which was initiated last November, has seen the discovery of an experimental treatment for glioblastoma, a brain tumour that affects around one in a million people.
It’s been a fascinating journey.
Now, the company is facing the question of how to proceed.
They are now in a position to announce the results of the first phase of the trial, but with so much happening in this trial, there’s not time to cover everything in detail.
We have, however, compiled the top tips that will help you stay informed.
You can follow the trial here.
Dicercas drug trials (Photo: dicernabot) It all starts with the drug trialsDicernamos is the name given to the Dicermatic compound (a compound made from the same family as a cancer drug called dicetrazolam) which is injected into the body.
Its effectiveness is believed to be around 95 per cent and there is currently no approved treatment.
This means the drug can be used in a number of different ways, but the main difference between the drug and other options is that the dicercamos has to be administered in a large, open-air environment, so it can be given in the morning and evening.
To be able to administer it in a safe manner, you have to get the patient to drink a small amount of the drug, and to be able do this in a controlled environment, you need a ‘tolerated dose’.
For this, Dicencas has partnered with a local clinic in the town of Giochi, which has developed a protocol for the treatment.
They also provide a number on-site treatments.
So far, there have been three trials: Dicencamos in humans (Image: www.dicercademy.it) A trial in mice, DICECAMOS in rats (Image: Dicerico di Biologia) This is the first trial in humans, which will be carried out by the University of Padova, the world’s oldest research university.
If all goes well, it will be followed by trials in mice.
These trials will be designed to measure the efficacy of the compound in humans and will follow up with a study on the effectiveness of the dacronate (dacronic acid) which will give us a more precise reading of the effectiveness in mice and humans.
It will also be possible to compare the efficacy between Dicenocarbinol, a newer drug, which is already approved in Europe, and Dicecamos, which hasn’t been approved yet.
Dicerico di biologia is a non-profit that has been working on a clinical trial for Dicensa since November last year, and will be involved in the development of the treatment, which will be administered by the clinic in Gioches, Italy.
More to come soon.